A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01781442|
Recruitment Status : Withdrawn
First Posted : February 1, 2013
Last Update Posted : May 1, 2013
|Condition or disease||Intervention/treatment|
|Renal Cell Carcinoma||Drug: Temsirolimus|
The Philippine Food and Drug Administration requires that a post marketing surveillance study be conducted nationwide and enroll approximately 3,000 study patients. In cases where the 3,000 patients will not be met, the total sample size can be reduced to 10% of the volume of drug use during the first year of it being marketed. Final sample size will be determined after one year of marketing authorization. The decision to use Torisel must be a joint decision made by the subject and the investigator.
The investigator must discuss product information with the subject as per usual practice.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study|
|Study Start Date :||June 2013|
|Estimated Primary Completion Date :||June 2015|
|Estimated Study Completion Date :||June 2015|
|Patient Arm- temsirolimus||
The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.
Treatment will continue until disease progression or unacceptable toxicity.
The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.
- Number of participants with Adverse Events [AEs] and Serious Adverse Events [SAEs] [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01781442
|Study Director:||Pfizer CT.gov Call Center||Pfizer|